Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 30 of 30 publications.
Skip to main content
Cook J, Jeuland M, Whittington D, Poulos C, Clemens J, Sur D, Anh DD, Agtini M, Bhuttai Z, DOMI Typhoid Economics Study Group . The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. Vaccine. 2008 Nov 25;26(50):6305-16.
Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson P, Plumb J. Cost-effectiveness of dabigatran etexilate for the primary prevention of venous thromboembolism in patients undergoing total hip or total knee replacement surgery. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece. [abstract] Value Health. 2008 Nov; 11(6):A404.
Hauber AB, Lam A, Fleishmann J, Wilson MR. European economic evaluation of OROS hydromorphone in the management of severe chronic cancer and non-cancer pain. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece. [abstract] Value Health. 2008 Nov; 11(6):A640.
Brogan AJ, Everhard F, Talbird SE, Hutt E, Zimovetz E. NRTI backbone pairs for treatment-naïve adults with HIV infection: a UK economic evaluation. Poster presented at the 9th International Congress on Drug Therapy in HIV Infection; November 2008.
Brogan AJ, Everhard F, Talbird SE, Hutt E. Cost-effectiveness of tenofovir/emtricitabine compared with other NRTI pairs in treatment-naïve adults with HIV infection in the United States. Poster presented at the 9th International Congress on Drug Therapy in HIV Infection; November 2008.
Zarkin GA, Cowell AJ, Dunlap LJ, Hicks KA, Keyes VS, Mills MJ. Simulating the costs and benefits of prison-based substance abuse treatment. Presented at the Addiction Health Services Research; October 2008.
Mitra D, Davis KL, Beam C, Medjedovic J, Rustgi V. Economic burden of hcv and hiv co-infection compared to hcv alone in a managed care population. Poster presented at the Joint Meeting of the American Society for Microbiology and Infectious Disease Society of America; October 2008.
Mitra D, Davis KL, Beam C, Medjedovic J, Rustgi V. Association between sustained virologic response and health care costs in patients with chronic hepatitis C virus: evidence from a US managed care database. Poster presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 2008.
Marton JP, Jackel JL, Carson RT, Rothermel CD, Friedman M, Menzin J. Costs of skin and skin structure infections due to Staphylococcus aureus: an analysis of managed-care claims. Curr Med Res Opin. 2008 Oct;24(10):2821-8.
Davis KL, Bapat BS, Bell TJ, Miller JD. Hospital costs, length of stay, and mortality associated with meningococcal disease in the United States. Poster presented at the 2008 Infectious Disease Society of America (IDSA) Annual Meeting; October 2008.
Wolowacz SE, Hess N, Brennan VK, Monz BU, Plumb JM. Cost-effectiveness of venous thromboembolism prophylaxis in total hip and knee replacement surgery: the evolving application of health economic modelling over 20 years. Curr Med Res Opin. 2008 Oct 1;24(10):2993-3006.
Turk DC, Dworkin RH, McDermott MP, Bellamy N, Burke LB, Chandler JM, Cleeland CS, Cowan P, Dimitrova R, Farrar JT, Hertz S, Heyse JF, Iyengar S, Jadad AR, Jay GW, Jermano JA, Katz NP, Manning DC, Martin SA, Max MB, McGrath P, McQuay HJ, Quessy S, Rappaport BA, Revicki DA, Rothman M, Stauffer JW, Svensson O, White RE, Witter J. Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials. Pain. 2008 Oct;139(3):485-93. doi: 10.1016/j.pain.2008.06.025.
Greene BL, Brown TM, Miller JD, Harshman R, Richerson G, Doyle JJ. Economic impact of the BP downshift program on blood pressure control among commercial driver license employees. Poster presented at the 2008 Academy of Managed Care Pharmacy Educational Conference; October 2008. [abstract] Am J Manag Care. 2008 Oct; 14(7).
Hicks KA, Zarkin GA, Cowell AJ, Dunlap LJ, Mills MJ, Keyes VS. A DES model for estimating the costs and benefits of prison-based substance abuse treatment. Poster presented at the 2008 INFORMS Annual Meeting; October 2008.
Hicks KA, Uzunangelov VJ, Lasry A, Sansom S. Allocating CDC's HIV prevention funds. Presented at the 2008 INFORMS Annual Meeting; October 2008.
Hicks KA, Richter A. Impact of uncertainty in hiv resource allocation. Presented at the 2008 INFORMS Annual Meeting; October 2008.
Graham CN, Borker R, Oppe M, Uyl-de Groot CA, Brogan AJ, Barber B. Cost-effectiveness of panitumumab plus best supportive care (BSC) compared with BSC alone in chemorefractory metastatic colorectal cancer (MCRC) patients (PTS) with wild-type (WT) KRAS tumor status in the Netherlands. Poster presented at the 33rd European Society for Medical Oncology (ESMO) Congress; September 2008.
Earnshaw SR, Graham CN, Irish WD, Sato R, Schnitzler MA. Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantation. J Am Soc Nephrol. 2008 Sep 1;19(9):1807-16.
Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AR. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity. Value Health. 2008 Jul 1;11(4):563-74.
Mitra D, Davis KL, Medjedovic J, Beam C, Rustgi VK. Health care utilization and costs associated with chronic hepatitis c in a managed care population. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A103.
Davis KL, Mitra D, Kotapati S. Direct economic burden of high-risk and metastatic melanoma: evidence from the SEER-medicare linked database. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A69-70.
Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi VK. Direct economic burden of chronic hepatitis c virus in a large managed care population. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A87.
Graham CN, Earnshaw SR, Raymond V. Cost-effectiveness of anidulafungin therapy in confirmed candidemia and other forms of invasive candidiasis in Canada. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. [abstract] Value Health. 2008 May; 11(3):A98.
Guh S, Chen XB, Poulos C, Qi Z, Cao JW, von Seidlein L, Chen JC, Wang XY, Xing ZC, Nyamete A, Clemens J, Whittington D. Comparison of cost-of-illness with willingness-to-pay estimates to avoid shigellosis: evidence from China. Health Policy Plan. 2008 Mar 1;23(2):125-36.
Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP, Martin SA, Sharma U. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008 Mar;35(3):502-14.
Wolowacz SE, Cameron DA, Tate HC, Bagust A. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. J Clin Oncol. 2008 Feb 20;26(6):925-33.
Richter A, Hicks KA. Costs of equity in hiv prevention. Presented at the CDC NCHSTP Seminar; February 2008.
Menzin J, Wygant G, Hauch O, Jackel JL, Friedman M. One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database. Curr Med Res Opin. 2008 Feb;24(2):461-8. doi: 10.1185/030079908X261096 .
Fagiolini A, Mauskopf JA, Wilson MR, Harnett J, Sanders KN, Kremer C. Development of a cost-effectiveness model for evaluating treatment of acute mania/mixed mania in bipolar i disorder. Poster presented at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders; February 2008.
Brodtkorb T, Henriksson M, Johannesen-Munk K, Thidell F. Cost-effectiveness of C-leg compared with non-microprocessor-controlled knees: a modeling approach. Arch Phys Med Rehabil. 2008;89(1):24-30.